Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021671 | 1.00 | ACE (0.31) | ACE | |
| SCHEMBL20021660 | 0.79 | POLB (0.36) | — | |
| SCHEMBL14600828 | 0.78 | SOAT1 (0.31) | ACE | |
| SCHEMBL6903692 | 0.78 | SOAT1 (0.31) | ACE | |
| SCHEMBL19222062 | 0.77 | POLB (0.40) | ACE | |
| SCHEMBL13522532 | 0.71 | POLB (0.42) | — | |
| SCHEMBL22767512 | 0.70 | HMGCR (0.36) | — | |
| SCHEMBL13930055 | 0.69 | KMT2A (0.36) | ACE | |
| SCHEMBL664811 | 0.69 | KMT2A (0.36) | ACE | |
| SCHEMBL4788721 | 0.69 | LMNA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118763-A1 | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180093999-A1 | NOVEL SUBSTITUTED AMINOTHIAZOLOPYRIMIDINEDIONE FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118763-A1 | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection | HAVCR2, ACE, ACE2 | ACE 2/4885 |
| US-20180093999-A1 | NOVEL SUBSTITUTED AMINOTHIAZOLOPYRIMIDINEDIONE FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | TPMT, ACE2, ACE | ACE 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.